Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Informed choice vs. no choice in colorectal cancer screening tests: a prospective cohort study in real-life screening practice.

Wong MC, Ching JY, Chan VC, Lam TY, Luk AK, Ng SC, Ng SS, Sung JJ.

Am J Gastroenterol. 2014 Jul;109(7):1072-9. doi: 10.1038/ajg.2014.136. Epub 2014 Jun 17.

PMID:
24935273
2.

Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys.

Wong MC, John GK, Hirai HW, Lam TY, Luk AK, Ching JY, Ng SS, Chan FK, Griffiths SM, Sung JJ.

Cancer Causes Control. 2012 Sep;23(9):1541-8. doi: 10.1007/s10552-012-0031-x. Epub 2012 Jul 27.

PMID:
22836914
3.

Prospective cohort study of compliance with faecal immunochemical tests for colorectal cancer screening in Hong Kong.

Wong MC, Ching JY, Lam TY, Luk AK, Hirai HW, Griffiths SM, Chan FK, Sung JJ.

Prev Med. 2013 Sep;57(3):227-31. doi: 10.1016/j.ypmed.2013.05.017. Epub 2013 May 31.

PMID:
23732241
4.

Regret on choice of colorectal cancer screening modality was associated with poorer screening compliance: a 4-year prospective cohort study.

Wong MC, Ching JY, Chan VC, Bruggemann R, Lam TY, Luk AK, Wu JC, Chan FK, Sung JJ.

PLoS One. 2015 Apr 14;10(4):e0125782. doi: 10.1371/journal.pone.0125782. eCollection 2015.

5.

Self-reported barriers to colorectal cancer screening in a racially diverse, low-income study population.

Quick BW, Hester CM, Young KL, Greiner KA.

J Community Health. 2013 Apr;38(2):285-92. doi: 10.1007/s10900-012-9612-6.

6.

Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.

Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66. doi: 10.1016/j.cgh.2013.03.013. Epub 2013 Mar 28.

PMID:
23542330
7.

Similar fecal immunochemical test results in screening and referral colorectal cancer.

van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar sive Droste JS, Fockens P, van der Hulst RW, Bouman AA, Jansen JB, Meijer GA, Dekker E, Mulder CJ.

World J Gastroenterol. 2012 Oct 14;18(38):5397-403. doi: 10.3748/wjg.v18.i38.5397.

8.

Should prior FIT results be incorporated as an additional variable to estimate risk of colorectal neoplasia? A prospective study of 5,813 screening colonoscopies.

Wong MC, Ching JY, Chan VC, Shum JP, Lam TY, Luk AK, Sung JJ.

PLoS One. 2014 Dec 5;9(12):e114332. doi: 10.1371/journal.pone.0114332. eCollection 2014.

9.

Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.

de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, Stegeman I, Kraaijenhagen RA, Fockens P, van Leerdam ME, Dekker E, Kuipers EJ.

Am J Gastroenterol. 2012 Oct;107(10):1570-8. doi: 10.1038/ajg.2012.249. Epub 2012 Jul 31.

PMID:
22850431
10.

Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany.

Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B.

BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183.

11.

The effect of primary care physician counseling on participation rate and use of sedation in colonoscopy-based colorectal cancer screening program--a randomized controlled study.

Boguradzka A, Wiszniewski M, Kaminski MF, Kraszewska E, Mazurczak-Pluta T, Rzewuska D, Ptasinski A, Regula J.

Scand J Gastroenterol. 2014 Jul;49(7):878-84. doi: 10.3109/00365521.2014.913191. Epub 2014 May 5.

PMID:
24797871
12.

The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.

Almog R, Ezra G, Lavi I, Rennert G, Hagoel L.

Eur J Cancer Prev. 2008 Oct;17(5):430-7. doi: 10.1097/CEJ.0b013e328305a0fa.

PMID:
18714185
13.

Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.

DeBourcy AC, Lichtenberger S, Felton S, Butterfield KT, Ahnen DJ, Denberg TD.

J Gen Intern Med. 2008 Feb;23(2):169-74. Epub 2007 Dec 21.

14.

Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years.

Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, Thomas JP, Vijan S, Inadomi JM.

Am J Gastroenterol. 2016 Jan;111(1):105-14. doi: 10.1038/ajg.2015.367. Epub 2015 Nov 3.

15.

Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.

Van Roosbroeck S, Hoeck S, Van Hal G.

Cancer Epidemiol. 2012 Oct;36(5):e317-24. doi: 10.1016/j.canep.2012.04.003. Epub 2012 May 5.

PMID:
22560885
16.

Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.

Inadomi JM.

J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S198-204. doi: 10.1111/j.1440-1746.2008.05556.x.

PMID:
19120898
17.

Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer.

Bujanda L, Sarasqueta C, Zubiaurre L, Cosme A, Muñoz C, Sánchez A, Martín C, Tito L, Piñol V, Castells A, Llor X, Xicola RM, Pons E, Clofent J, de Castro ML, Cuquerella J, Medina E, Gutierrez A, Arenas JI, Jover R; EPICOLON Group.

Gut. 2007 Dec;56(12):1714-8. Epub 2007 Mar 30.

18.

Challenges in the management of positive fecal occult blood tests.

Rao SK, Schilling TF, Sequist TD.

J Gen Intern Med. 2009 Mar;24(3):356-60. doi: 10.1007/s11606-008-0893-5. Epub 2009 Jan 8.

19.

The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial.

Griffith JM, Lewis CL, Brenner AR, Pignone MP.

BMC Med Inform Decis Mak. 2008 Jan 24;8:4. doi: 10.1186/1472-6947-8-4.

20.

Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.

Tam TK, Ng KK, Lau CM, Lai TC, Lai WY, Tsang LC.

Hong Kong Med J. 2011 Oct;17(5):350-7.

Items per page

Supplemental Content

Write to the Help Desk